Abstract：OBJECTIVE To develop a population pharmacokinetics (PPK) model of polymyxin B (PB) in Chinese sepsis patients. METHODS A total of 16 ICU sepsis patients with multidrug-resistant Gram-negative bacterial infections were included. On the fifth dose, blood specimens were collected before PB administration and up to 12 h after PB dosing. The PPK model was developed by nonlinear mixed effects modeling. RESULTS The PPK character of PB was best described by a two-compartment model. No clinical tested data of patients was identified as a covariate affected the PK parameters of polymyxin B in the studied sepsis population. The individual PB dosage adjustment should based on the PK target and MIC of microorganism in sepsis patients. CONCLUSION The PPK model of PB in sepsis is established successfully and could provide basis for the individualized dosage regimen in adult sepsis patients.
张俊, 张素枝, 孙志, 韩冰, 孔羽, 周霖, 朱振峰, 罗永刚, 张晓坚. 多黏菌素B在脓毒血症患者中的群体药动学研究[J]. 中国药学杂志, 2021, 56(9): 744-748.
ZHANG Jun, ZHANG Su-zhi, SUN Zhi, HAN Bing, KONG Yu, ZHOU Lin, ZHU Zhen-feng, LUO Yong-gang, ZHANG Xiao-jian. Population Pharmacokinetics of Polymyxin B in Patients with Sepsis. Chinese Pharmaceutical Journal, 2021, 56(9): 744-748.
WANG M, WEI H, ZHAO Y, et al. Analysis of multidrug-resistant bacteria in 3 223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China[J]. Bosn J Basic Med Sci, 2019, 19(1):86-93.
[2]
MAO T, ZHAI H, DUAN G, et al. Patterns of drug-resistant bacteria in a general hospital, China, 2011-2016[J]. Pol J Microbiol, 2019, 68(2):225-232.
[3]
CUNHA B A. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited[J]. Med Clin North Am, 2006, 90(6):1089-1107.
[4]
ZAVASCKI A P, GOLDANI L Z, LI J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review[J]. J Antimicrob Chemother, 2007, 60(6):1206-1215.
[5]
STORM D R, ROSENTHAL K S, SWANSON P E. Polymyxin and related peptide antibiotics[J]. Annu Rev Biochem, 1977, 46(1):723-763.
[6]
ROBERTS J A, JOYNT G M, CHOI G Y, et al. How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics[J]. Int J Antimicrob Agents, 2012, 39(3):187-192.
[7]
TSUJI B T, POGUE J M, ZAVASCKI A P, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)[J]. Pharmacotherapy, 2019, 39(1):10-39.
[8]
MANCHANDANI P, THAMLIKITKUL V, DUBROVSKAYA Y, et al. Population pharmacokinetics of polymyxin B[J]. Clin Pharmacol Ther, 2018, 104(3):534-538.
[9]
NICOLAU D P, QUINTILIANI R, NIGHTINGALE C H. Antibiotic kinetics and dynamics for the clinician[J]. Med Clin North Am, 1995, 79(3):477-495.
[10]
SANDRI A M, LANDERSDORFER C B, JACOB J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens[J]. Clin Infect Dis, 2013, 57(4):524-531.
[11]
COCKCROFT D W, GAULT M H. Prediction of creatinine clearance from serum creatinine[J]. Nephron, 1976, 16(1):31-41.
[12]
YU X B, JIAO Z, ZHANG C H, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions[J]. Br J Clin Pharmacol, 2020, 87(11):14576.
[13]
KUBIN C J, NELSON B C, MIGLIS C, et al. Population pharmacokinetics of intravenous polymyxin B from clinical samples[J]. Antimicrob Agents Chemother, 2018, 62(3):e01493-17.
[14]
WANG P, ZHANG Q, ZHU Z, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections[J]. Front Pharmacol, 2020, 11:829.
[15]
AVEDISSIAN S N, MIGLIS C, KUBIN C J, et al. Polymyxin B pharmacokinetics in adult cystic fibrosis patients[J]. Pharmacotherapy, 2018, 38(7):730-738.
[16]
MIGLIS C, RHODES N J, AVEDISSIAN S N, et al. Population pharmacokinetics of polymyxin B in acutely Ⅲ adult patients[J]. Antimicrob Agents Chemother, 2018, 62(3):e01475-17.
[17]
THAMLIKITKUL V, DUBROVSKAYA Y, MANCHANDANI P, et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency[J]. Antimicrob Agents Chemother, 2017, 61(1):e01337-16.
[18]
KUBIN C J, NELSON B C, MIGLIS C, et al. Population pharmacokinetics of intravenous polymyxin B from clinical samples[J]. Antimicrob Agents Chemother, 2018, 62(3):e01493-17.
[19]
ZAVASCKI A P, GOLDANI L Z, CAO G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients[J]. Clin Infect Dis, 2008, 47(10):1298-1304.
[20]
ELIAS L S, KONZEN D, KREBS J M, et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic[J]. J Antimicrob Chemother, 2010, 65(10):2231-2237.
[21]
DUDHANI R V, TURNIDGE J D, NATION R L, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models[J]. J Antimicrob Chemother, 2010, 65(9):1984-1990.
2021, Vol. 56 
